我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 日内瓦医学教育与研究基金会
  • ICMJE
分享此页面

抽象的

Zoonotic Amebiasis: A Journey from Epidemiology to Treatment Strategy

Li X

The protozoan parasite Entamoeba histolytica is the cause of the disease known as amebiasis, which typically manifests as acute diarrhea, dysentery, amebic colitis, and amebic liver abscesses. E. histolytica is the fourth leading parasitic cause of human death. It mostly infects children in developing nations and is spread through contamination of food and water. Entamoeba sp. is present in the majority of infected individuals. Asymptomatically colonizes the large intestine and resolves on its own, whereas in others, the parasite can spread to soft organs and cause abscesses by breaching the mucosal epithelial barrier and causing amebic colitis. The treatment for invasive amebiasis that is both recommended and most commonly used is metronidazole (MTZ). Despite the fact that no amebiasis vaccine has yet been approved for human clinical trials, numerous recent vaccine development studies offer promise. For the counteraction and control of amebiasis, improvement of water cleansing frameworks and cleanliness practices could diminish illness frequency. The epidemiology, transmission, clinical signs, pathogenesis, diagnosis, treatment, prevention, and control of zoonotic amebiasis are the primary topics of this review.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。